Currently, there are 50.76M common shares owned by the public and among those 40.48M shares have been available to trade.
Insiders at the company have transacted a total of 24 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 24 of these insider trades were purchases, accounting for 1,379,865 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 0.1010, down -2.91%. The company’s stock has a 5-day price change of -14.03% and -72.14% over the past three months. JAGX shares are trading -36.06% year to date (YTD), with the 12-month market performance down to -97.87% lower. It has a 12-month low price of $0.09 and touched a high of $5.04 over the same period. JAGX has an average intraday trading volume of 9.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.63%, -49.83%, and -76.43% respectively.
Institutional ownership of Jaguar Health Inc (NASDAQ: JAGX) shares accounts for 1.16% of the company’s 50.76M shares outstanding.
It has a market capitalization of $4.91M and a beta (3y monthly) value of 1.42. The earnings-per-share (ttm) stands at -$6.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.43% over the week and 12.84% over the month.
Analysts forecast that Jaguar Health Inc (JAGX) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$9 a year ago. EPS should shrink at an annualized rate of 40.00% over the next five years, compared to 80.25% over the past 5-year period.
Looking at the support for the JAGX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 07, 2021, with the firm’s price target at $5.
